For the first time, Stanford University, under the auspices of its Biodesign program, will sponsor a hands-on workshop for entrepreneurs in the medical device sectors. START-UP assembled a group of industry leaders who will be among the participating faculty, including David Douglass and John Maroney of Delphi Ventures, Richard Ferrari and Jay Watkins of De Novo Ventures, Wilson Sonsini's Casey McGlynn, and Paul Yock, MD, of Stanford's department of bioengineering, to discuss the do's and don'ts of early-stage entrepreneurship.
By Stephen Levin
Current business school curriculums are replete with entrepreneurship programs for MBA candidates, and senior corporate officers can have their pick...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.
Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.
The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.
Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.
Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.
